



**Regulation of Human 5-Aminolevulinate Synthase 2
Expression During Erythroid Differentiation and Its Role in
X-Linked Sideroblastic Anaemia**

**A thesis submitted to the University of Adelaide for the degree of
Doctor of Philosophy**

by

Tania Dell'Oso B.Sc. Hons (University of Adelaide)

**School of Molecular and Biomedical Science
University of Adelaide
Adelaide, South Australia, Australia**

March, 2003

TABLE OF CONTENTS

THESIS SUMMARY	VI
DECLARATION	VIII
ACKNOWLEDGEMENTS	IX
ABBREVIATIONS.....	XI
<u>CHAPTER 1: GENERAL INTRODUCTION</u>.....	<u>1</u>
1.1 INTRODUCTION	1
1.2 HAEMATOPOIESIS	2
1.2.1 THE ORIGIN OF DEFINITIVE HAEMATOPOIETIC STEM CELLS	2
1.3 ERYTHROPOIESIS	3
1.3.1 ERYTHROPOIETIN AND ERYTHROPOIETIN RECEPTOR SIGNALLING	5
1.4 TRANSCRIPTION FACTORS REGULATING ERYTHROPOIESIS	7
1.4.1 STEM CELL LEUKEMIA (SCL)	7
1.4.2 LIM-ONLY PROTEIN 2 (LM02)	8
1.4.3 GATA-2	9
1.4.4 C-MYB	9
1.4.5 GATA-1	10
1.4.6 FOG	11
1.4.7 EKLF	11
1.4.8 OTHER KRUPPEL-LIKE FAMILY MEMBERS REGULATING ERYTHROPOIESIS.....	13
1.4.9 NF-E2	13
1.4.10 PU.1	15
1.4.11 EFFECT OF A TRANSCRIPTIONAL COACTIVATOR ON ERYTHROID TRANSCRIPTION FACTORS.....	15
1.5 GLOBIN GENE EXPRESSION DURING ERYTHROPOIESIS	18
1.5.1 THE GLOBIN GENE CLUSTER	18
1.5.2 REGULATION OF β -GLOBIN GENE EXPRESSION	19
1.6 HAEM BIOSYNTHESIS	23
1.7 ALAS.....	24
1.7.1 PROPERTIES OF ALAS	24
1.7.2 MECHANISM OF ALAS	26
1.7.3 ALAS GENE STRUCTURE	27
1.8 REGULATION OF ALAS1.....	28

1.9 REGULATION OF ALAS2.....	29
1.9.1 TRANSCRIPTIONAL REGULATION OF ALAS2.....	30
1.9.2 REGULATION OF ALAS2 TRANSLATION.....	33
1.9.3 REGULATION OF ALAS2 BY HAEM	35
1.9.4 HYPOXIC REGULATION OF ALAS2 EXPRESSION	36
1.9.5 ROLE OF ALAS2 EXPRESSION IN ERYTHROID CELL DIFFERENTIATION	36
1.9.6 MODEL FOR REGULATION OF ALAS2	37
1.10 SIDEROBLASTIC ANAEMIA.....	37
1.10.1 CHARACTERISTICS OF SIDEROBLASTIC ANAEMIA.....	37
1.10.2 IMPLICATION OF ALAS2 IN XLSA.....	41
1.10.3 A GENE INVOLVED IN A DIFFERENT FORM OF XLSA.....	43
1.10.4 TREATMENT OF SIDEROBLASTIC ANAEMIA	44
1.11 AIMS.....	45

CHAPTER TWO: MATERIALS AND METHODS **47**

2.1 MATERIALS	47
2.1.1 DRUGS, CHEMICALS AND REAGENTS.....	47
2.1.2 RADIOCHEMICALS	47
2.1.3 ENZYMES.....	47
2.1.4 BUFFERS	48
2.1.5 CLONING VECTORS.....	48
2.1.6 CLONED DNA SEQUENCES.....	48
2.1.7 SYNTHETIC OLIGONUCLEOTIDES	49
i) Oligonucleotides for sequencing plasmid constructs	49
ii) Oligonucleotides used in the mutagenesis of human ALAS2 Intron 8	49
iii) Sequences of the sense strand of synthetic oligonucleotides used in gel shift assays	49
iv) Oligonucleotides for the generation of XLSA point mutations	50
2.1.8 BACTERIAL STRAINS	50
2.1.9 BACTERIAL GROWTH MEDIA.....	51
2.1.10 TISSUE CULTURE CELL LINES AND MEDIA.....	51
i) Cell Lines	52
ii) Solutions.....	52
iii) Media	52
2.1.11 MISCELLANEOUS	53

2.2 RECOMBINANT DNA METHODS	54
2.2.1 GENERAL DNA METHODS	54
2.2.2 PLASMID DNA PREPARATION	54
2.2.3 RESTRICTION ENZYME DIGESTIONS OF DNA	55
2.2.4 PREPARATION OF CLONING VECTORS.....	55
2.2.5 PREPARATION OF DNA RESTRICTION FRAGMENTS	55
2.2.6 LIGATION OF DNA	56
2.2.7 TRANSFORMATION OF <i>E. COLI</i> WITH RECOMBINANT PLASMIDS.....	56
i) Preparation of Competent <i>E. coli</i>	56
ii) Transformation of Competent Bacteria.....	56
2.2.8 DNA SEQUENCE ANALYSIS.....	57
2.2.9 PREPARATION OF RADIOLABELLED DNA PROBES	57
i) Oligo-Labeling DNA	57
ii) 5' End-Labeling of Synthetic DNA oligonucleotides	58
2.2.10 PREPARATION OF RADIOLABELLED DNA MARKERS	58
2.2.11 OLIGONUCLEOTIDE SITE-DIRECTED MUTAGENESIS	59
i) Mutagenesis Reaction	59
ii) Selection of Clones Containing the Mutation	59
2.3 REPORTER AND EXPRESSION CONSTRUCTS UTILISED IN THE INVESTIGATION OF ALAS2 TRANSCRIPTIONAL REGULATION	59
2.3.1 ALAS2 PROMOTER/REPORTER GENE PLASMIDS	60
2.3.2 ALAS2 INTRON/REPORTER GENE CONSTRUCTS	60
2.3.3 SITE-DIRECTED MUTAGENESIS OF THE HUMAN ALAS2 INTRON 8 SEQUENCE.....	61
2.3.4 WILD TYPE AND MUTANT E1A AND P300 EXPRESSION CONSTRUCTS	61
2.4 ALAS2 TARGETING CONSTRUCTS.....	62
2.4.1 SYNTHESIS OF THE ALAS2 EXON 8 C1159G MUTANT TARGETING CONSTRUCT	62
2.4.2 SYNTHESIS OF THE ALAS2 EXON 9 C1228T MUTANT TARGETING CONSTRUCT.....	62
2.4.3 CONSTRUCTION OF ALAS2 TARGETING VECTOR CONTAINING THE PGKNEO ^R /HSVTK SELECTION CASSETTE.....	63
2.5 METHODS FOR THE <i>IN VITRO</i> DIFFERENTIATION OF AN ERYTHROID CELL LINE.....	63
2.5.1 CELL MAINTENANCE	63
2.5.2 <i>IN VITRO</i> DIFFERENTIATION OF J2E CELLS	64
i) Erythropoietin induced differentiation of the J2E cell line.....	64
ii) Staining of cells with benzidine, a stain for haemoglobin production.....	64

2.6 METHODS FOR EXPRESSION OF REPORTER CONSTRUCTS IN TISSUE CULTURE CELL LINES.....	64
2.6.1 TRANSIENT TRANSFECTION OF THE J2E CELL LINE.....	64
2.6.2 LUCIFERASE REPORTER GENE ASSAY IN J2E CELLS	65
2.7 METHODS FOR GENE TARGETING EMBRYONIC STEM CELLS.....	65
2.7.1 CELL MAINTENANCE	65
i) E14TG2a Embryonic Stem Cells	65
ii) W9.5 Embryonic Stem Cells.....	66
2.7.2 IRRADIATION OF STO ^R FIBROBLAST CELLS.....	66
2.7.3 STABLE TRANSFECTION OF ES CELLS WITH TARGETING VECTOR DNA VIA ELECTROPORATION.	66
i) E14TG2a ES Cells	66
ii) W9.5 ES Cells	67
2.7.4 PICKING OF SELECTION RESISTANT COLONIES	68
2.7.5 FREEZING OF TARGETED CLONES	68
2.7.6 HISTOCHEMICAL STAINING FOR β -GALACTOSIDASE ACTIVITY	69
2.7.7 KARYOTYPING OF ALAS2 TARGETED ES CELL LINES	69
2.8 SOUTHERN BLOT ANALYSIS AND HYBRIDISATION CONDITIONS.....	69
2.8.1 ISOLATION OF GENOMIC DNA FROM ES CELLS	69
2.8.2 SOUTHERN BLOT ANALYSIS	70
2.8.3 STRIPPING OF THE FILTER	70
2.9 METHODS FOR ELECTROPHORETIC MOBILITY SHIFT ASSAYS	70
2.9.1 PREPARATION OF NUCLEAR PROTEIN EXTRACTS	71
2.9.2 PREPARATION OF RADIOLABELLED ANNEALED OLIGONUCLEOTIDE PROBES	71
2.9.3 ELECTROPHORETIC MOBILITY SHIFT ASSAY	71

CHAPTER 3: TRANSCRIPTIONAL REGULATION OF THE HUMAN ALAS2 GENE IN RESPONSE TO ERYTHROPOIETIN INDUCED DIFFERENTIATION OF ERYTHROID CELLS

3.1 INTRODUCTION	72
3.2 RESULTS	75
3.2.1 EPO INDUCED DIFFERENTIATION OF J2E ERYTHROID CELLS.....	75
3.2.2 THE MINIMAL LENGTH OF THE HUMAN ALAS2 PROMOTER REQUIRED FOR A RESPONSE TO EPO IS 293 BASE PAIRS	75

3.2.3 LOCALISATION OF EPO RESPONSIVE ENHANCER ELEMENTS WITHIN THE HUMAN ALAS2 GENE	77
3.2.4 DETERMINATION OF TRANSCRIPTION FACTOR BINDING SITES WITHIN INTRON 8 THAT ARE CRITICAL TO EPO ENHANCED TRANSCRIPTION OF THE HUMAN ALAS2 PROMOTER.....	79
3.2.5 BINDING OF GATA-1 TO THE ENHANCER IN HUMAN ALAS2 INTRON 8 IS INDEPENDENT OF EPO STIMULATION	81
3.2.6 THE EFFECT OF EPO ON THE BINDING OF CACCC-ASSOCIATED PROTEINS TO SITES IN HUMAN ALAS2 INTRON 8	82
3.2.7 INVESTIGATING THE ROLE OF CBP/P300 COACTIVATOR IN THE TRANSCRIPTIONAL REGULATION OF ALAS2	86
3.3 DISCUSSION.....	90

CHAPTER 4: GENERATION OF A MURINE MODEL FOR X-LINKED

SIDEROBLASTIC ANAEMIA **103**

4.1 INTRODUCTION	103
4.2 RESULTS	107
4.2.1 TARGETING OF THE ALAS2 LOCUS IN E14TG2A ES CELLS	107
4.2.2 INTRODUCTION OF THE XLSA-ASSOCIATED MUTATION (C1228T) INTO EXON 9 OF THE ALAS2 LOCUS OF THE HPRT-POSITIVE R3 ES CELL LINE	110
4.2.3 TARGETING OF THE ALAS2 LOCUS IN W9.5 ES CELLS	113
4.2.4 STRATEGY FOR THE COMMERCIAL GENERATION OF AN ALAS2 TARGETED ES CELL LINE	117
4.2.5 CONSTRUCTION OF A ALAS2 C1159G TARGETING VECTOR	118
4.2.6 SCREENING STRATEGY TO IDENTIFY ALAS2 TARGETED W9.5 ES CELLS PRODUCED BY OZGENE	119
4.3 DISCUSSION.....	121

CHAPTER 5: FINAL SUMMARY **127**

REFERENCE LIST **133**

THESIS SUMMARY

Haem is required for many cellular processes including haemoglobin synthesis in erythroid cells, where the majority of the haem in the body is produced and utilised. Its synthesis requires tight regulation to prevent toxic levels of free haem from arising. 5-Aminolevulinate synthase 2 (ALAS2) is the first and rate limiting enzyme in the biosynthesis of haem in erythroid cells. Thus, the regulation of ALAS2 expression is critical for maintaining and controlling haem production during the process of erythroid cell differentiation. A major aim of this study was to identify the regulatory elements within the ALAS2 gene that are involved in controlling transcription of ALAS2 during erythropoietin (Epo) stimulated erythroid differentiation. In order to investigate the regulation of ALAS2 transcription in the context of red blood cell maturation, an erythroid cell line, J2E, that terminally differentiates in response to Epo treatment was employed in this study.

Human ALAS2 promoter deletion studies demonstrated that the first 293 bp of the proximal promoter was sufficient to enhance transcription in response to Epo induced differentiation of the J2E cells. Introns 1 and 8 exhibited Epo responsive enhancer activity with intron 8 proving to be the stronger transcriptional activator in response to Epo. Transcription factor binding sites located in the 3' end of intron 8 that are critical to intron 8 Epo responsive enhancer activity were also identified. Preliminary studies on the effect of the coactivators CREB binding protein (CBP) and p300 on ALAS2 expression in response to Epo stimulation were conducted and suggested a potential involvement of these factors in regulating ALAS2 transcription.

Defective haem synthesis, as a result of point mutations in the human ALAS2 gene, has been implicated in a blood disorder called X-linked sideroblastic anaemia (XLSA). XLSA is characterised by the presence of iron loaded mitochondria surrounding the nucleus in erythroblasts of the bone marrow. Anaemia, associated with a cycle of ineffective erythropoiesis that is linked to increased intestinal iron absorption and the secondary effect of iron overload is exhibited by XLSA patients. Point mutations in the ALAS2 gene of XLSA probands have been identified and two associated mutations, C1215G in exon 8 and C1283T in exon 9 were selected as a basis for a murine model for XLSA. Thus, the aim of this project was to develop an animal model for XLSA to investigate the role of ALAS2 in this blood disorder and the associated defects in iron metabolism. A gene targeting approach using

embryonic stem (ES) cells was employed and several strategies trialed. A potential ALAS2 targeted ES cell line containing the C1159G point mutation in exon 8 (equivalent to the human mutation) was generated, with further characterisation required.